Literature DB >> 31984399

Identification of the key physiological characteristics of Lactobacillus plantarum strains for ulcerative colitis alleviation.

Yang Liu1, Yingyue Sheng2, Qiqi Pan1, Yuzheng Xue2, Leilei Yu1, Fengwei Tian3, Jianxin Zhao1, Hao Zhang4, Qixiao Zhai3, Wei Chen5.   

Abstract

Lactobacillus plantarum is a probiotic that is widely used to prevent ulcerative colitis (UC). However, the effects of this species are strain-specific. We believe that the physiological characteristics of L. plantarum strains may affect their UC-alleviating function. Therefore, this study investigated the relationship between the alleviating effect of L. plantarum strains on UC and their physiological characteristics in vitro. The physiological characteristics of 14 L. plantarum strains were assayed in vitro, including gastrointestinal transit tolerance, oligosaccharide fermentation, HT-29 cell adhesion, generation time, exopolysaccharide production, acetic acid production, and conjugated linoleic acid (CLA) synthesis. To create animal models, colitis was established in C57BL/6 mice by adding 3.5% dextran sulfate sodium to drinking water for 7 days. L. plantarum strains with significantly different physiological characteristics were orally administered to the mice at a dose of 3 × 109 CFU. The results indicated that among the tested L. plantarum strains, L. plantarum N13 and L. plantarum CCFM8610 significantly alleviated colitis in the mice, as observed from the restoration of the body weight and disease activity index (DAI) score, recovery of the gut microbiota composition, reduced expression of pro-inflammatory cytokines, and significantly inhibited expression of p65. Correlation analysis indicated that four of the measured physiological characteristics (gastrointestinal transit tolerance, HT-29 cell adhesion, generation time, and CLA synthesis) were related to the UC-alleviating effects to different degrees. The strongest correlation was observed between the CLA synthesis ability and UC-alleviating effects (with Pearson correlation coefficients for IL-1β, IL-6, IL-17F, TNF-α, myeloperoxidase, and the DAI all below -0.95). The ability to synthesize CLA may be the key physiological characteristic of L. plantarum in UC alleviation. Our findings may contribute to the rapid screening of lactic acid bacterial strains with UC-alleviating effects.

Entities:  

Year:  2020        PMID: 31984399     DOI: 10.1039/c9fo02935d

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  5 in total

1.  Lactiplantibacillus plantarum-12 Alleviates Inflammation and Colon Cancer Symptoms in AOM/DSS-Treated Mice through Modulating the Intestinal Microbiome and Metabolome.

Authors:  Fenglian Ma; Mengying Sun; Yinglong Song; Arong Wang; Shujuan Jiang; Fang Qian; Guangqing Mu; Yanfeng Tuo
Journal:  Nutrients       Date:  2022-05-03       Impact factor: 6.706

2.  Screening and Probiotic Potential Evaluation of Bacteriocin-Producing Lactiplantibacillus plantarum In Vitro.

Authors:  Yushan Bu; Yisuo Liu; Yinxue Liu; Shaolei Wang; Qiqi Liu; Haining Hao; Huaxi Yi
Journal:  Foods       Date:  2022-05-27

3.  Anti-Adhesion Effects of Lactobacillus Strains on Caco-2 Cells Against Escherichia Coli and Their Application in Ameliorating the Symptoms of Dextran Sulfate Sodium-Induced Colitis in Mice.

Authors:  Tao Wang; Huimin Sun; Jiaxin Chen; Lingli Luo; Yaxin Gu; Xin Wang; Yuanyuan Shan; Yanglei Yi; Bianfang Liu; Yuan Zhou; Xin Lü
Journal:  Probiotics Antimicrob Proteins       Date:  2021-04-14       Impact factor: 4.609

4.  A Mixture of Lactobacillus fermentum HFY06 and Arabinoxylan Ameliorates Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Mice.

Authors:  Fang Li; Hui Huang; Fulejia Zhu; Xianrong Zhou; Zhennai Yang; Xin Zhao
Journal:  J Inflamm Res       Date:  2021-12-06

5.  Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis.

Authors:  Peng Yu; Chuxin Ke; Jiaxin Guo; Xiuling Zhang; Bailiang Li
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.